Subtype
Malignant Hepatobiliary Neoplasm
CI-CAN-00001136Explore in graph →
1,159 active trials17 approved drugs42 evidence items
- NCIt
- C8609
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001136Explore in graph →
Clinical trials
5,025 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (560)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06968195 | Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma | suspended | Phase 1 | 24 | Roswell Park Cancer InstituteOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06620302 | Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma | suspended | Phase 1 / Phase 2 | 81 | Children's Oncology GroupNETWORK | 1 | Aug 24, 2026 |
| clinicaltrials |
| NCT05791448 | AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease | suspended | Phase 1 | 36 | University of Southern CaliforniaOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT05377827 | Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies | suspended | Phase 1 | 6 | Washington University School of MedicineOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT05603572 | KAT-101 in Subjects With Hepatocellular Carcinoma (HCC) | suspended | Phase 1 / Phase 2 | 148 | Primocure PharmaINDUSTRY | 1 | Jun 5, 2025 | clinicaltrials |
| NCT04506983 | GPC3-CAR-T Cells for the Hepatocellular Carcinoma | suspended | Phase 1 | 12 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Feb 14, 2022 | clinicaltrials |
| NCT02026362 | Multiple Antigen Specific Cell Therapy (MASCT) for Hepatocellular Carcinoma(HCC) Patients After Radical Resection or Radio Frequency Ablation(RFA).(HCC DC CTL) | suspended | Phase 1 / Phase 2 | 100 | HRYZ Biotech Co.INDUSTRY | 1 | Oct 18, 2017 | clinicaltrials |
| NCT00624182 | Gemcitabine With Peptide Vaccine Therapy in Treating Patients With Bile Duct Cancer | suspended | Phase 1 | 9 | Akita University HospitalOTHER | 1 | Jun 23, 2015 | clinicaltrials |
| NCT00909558 | Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer | suspended | Phase 1 | 24 | Envita Medical Center, Inc.INDUSTRY | 1 | Feb 24, 2010 | clinicaltrials |
Data updated 15 days agoSource updated Sep 15, 2026source: clinicaltrials